Latest Videos Archives

Clinical Trials in MIBC and NMIBC

Posted by Daniel P. Petrylak, MD | Dec 2024

Daniel P. Petrylak, MD, discusses advancements in treating urothelial carcinoma, emphasizing innovative therapies for BCG-refractory, recurrent, and metastatic disease.

In this 10-minute talk, Petrylak highlights Dr. Neil Shore’s INSTIL trial, a significant phase 3 study evaluating the adenovirus interferon agent nadofaragene firadenovec. Dr. Petrylak also discusses how immune checkpoint inhibitors, such as pembrolizumab, are moving into early-stage treatment and combined with BCG for non-cystectomy patients.

The discussion transitions to innovative drug delivery systems, such as a “pretzel” device designed for intravesical drug release.
Dr. Petrylak shares new trials in treating metastatic carcinoma that focus on minimizing side effects linked to conventional drugs like enfortumab vedotin by introducing smaller, less immunogenic agents. These trials, including a DEVAL phase 1 dose-escalation study, underscore the importance of these targeted innovations in battling this challenging cancer.

Metastatic Castrate Sensitive Prostate Cancer

Posted by Rana R. McKay, MD | Dec 2024

Rana McKay, MD, discusses the evolving treatment strategies for metastatic hormone-sensitive prostate cancer (mHSPC), emphasizing advancements over the past decade. In this 20-minute presentation, McKay shares that prostate cancer remains a leading cause of mortality among men. While traditional androgen deprivation therapy (ADT) has long been the cornerstone treatment, newer approaches integrating chemotherapy, androgen receptor signaling inhibitors (ARSIs), and combination regimens have transformed patient outcomes. She refers to landmark studies like CHARTED, LATITUDE, and STAMPEDE, highlighting the benefits of early intensifying treatment and showing significant survival advantages with doublet and triplet therapies. She also shares recent trials, including PIECE-1 and ARASENS, that underscore the effectiveness of adding agents like abiraterone or darolutamide to ADT and docetaxel for high-risk, high-volume disease.

Dr. McKay asserts clinical decision-making now incorporates disease factors such as volume and risk, patient comorbidities, and drug-specific considerations like toxicity profiles and cost. Emerging genomic and molecular tools are poised to refine treatment personalization further, with ongoing trials exploring the optimal integration of novel agents.

Genetic Testing in Prostate Cancer Management

Posted by Abhinav Sidana, MD, MPH | Dec 2024

Abhinav Sidana, MD, MPH, highlights the critical role of genetic testing in prostate cancer management, aiming to familiarize urologists with its fundamentals and practical application. In this 17-minute presentation, Dr. Saadana shares a detailed case study of a healthy 63-year-old male with prostate cancer, underscoring the importance of DNA damage repair pathway genes.

Dr. Sidana categorizes genetic mutations into germline mutations and somatic mutations. Both are essential in identifying actionable genetic alterations that guide early diagnosis, prognosis, and treatment. He emphasizes the prognostic implications of genetic testing in driving treatment strategies. Dr. Sidana highlights the utility of multi-gene panels that assess a broad range of cancers and the importance of genetic counseling in addressing the clinical and psychosocial aspects of testing. Current guidelines recommend testing for high-risk, metastatic, or familial prostate cancer cases.

Course Introduction: Description of Terminology and Review of Guidelines

Posted by Natalie Reizine, MD | Dec 2024

Natalie Reizine, MD, delves into the current understanding, treatment options, and future directions for managing prostate cancer. In this 23-minute presentation, Dr. Reizine discusses disease progression, from localized stages to advanced and metastatic forms, emphasizing the evolving role of imaging technologies like PSMA PET scans in early detection and monitoring.

Dr. Reizine reviews the biology of prostate cancer, particularly its reliance on androgen receptor signaling, which forms the foundation for many therapeutic strategies. She highlights the importance of understanding disease-specific nuances, such as low versus high-volume metastases, to tailor treatment strategies.

Bone health in prostate cancer is emphasized, particularly for patients on long-term ADT. Similarly, dental care and endocrinology referrals are underscored as part of comprehensive management.

Dr. Reizine focuses on emerging therapies and personalized medicine approaches, with attention given to biomarkers like DNA damage repair mutations and new treatment modalities, including PARP inhibitors, radioligand therapies, and T-cell activating constructs. She underscores the need for improved predictive and prognostic biomarkers to effectively refine therapy selection and sequence treatments.

Optimizing Flow: Practical AI Applications in Urology

Posted by Arun Rai, MD, MBA, MS | Dec 2024

Arun Rai, MD, MBA, MS, explores how artificial intelligence can address inefficiencies in healthcare administration and improve patient workflows, particularly in urology. In this 15-minute presentation, Dr. Rai emphasizes that while clinical AI applications are advancing, many opportunities lie in streamlining administrative processes. AI offers solutions to automate repetitive tasks like billing, scheduling, and operational workflows, reducing costs and freeing up staff for more critical work.

The presentation highlights a real-world example from Northwell Health: AI-based scheduling models significantly reduced wait times for patients with prostate cancer and kidney masses. By leveraging data from billing, diagnosis, and operational systems, the models improved access to specialized care, ensuring timely treatment.

The talk also outlines a practical roadmap for developing AI solutions, emphasizing the need to define clear problems, ensure high-quality data, validate models in real-world settings, and implement scalable, user-focused systems.